SILENCE THERAP. SP.ADR/1 (XRP2) — Cash Flow Reinvestment Rate

Latest as of December 2021: 1.67x

SILENCE THERAP. SP.ADR/1 (XRP2) has a Cash Flow Reinvestment Rate of 1.67x as of December 2021, reinvesting €15.30 Million (capex €1.80 Million plus investments €13.50 Million) from operating cash flow of €9.19 Million. Explore reinvestment intensity of SILENCE THERAP. SP.ADR/1 to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

1.67x

(Capex + Investments) / Operating CF

Total Reinvested

€15.30 Million

Capex + Investments

Operating Cash Flow

€9.19 Million

EUR

Capital Expenditures

€1.80 Million

EUR

SILENCE THERAP. SP.ADR/1 Cash Flow Reinvestment Rate (2021–2021)

Historical reinvestment intensity for SILENCE THERAP. SP.ADR/1 across 1 annual periods. Also explore balance sheet size of SILENCE THERAP. SP.ADR/1 for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for SILENCE THERAP. SP.ADR/1 (2021–2021)

Year-by-year capital reinvestment analysis for SILENCE THERAP. SP.ADR/1. For live market cap and broader valuation context, see SILENCE THERAP. SP.ADR/1 (XRP2) total market value.

Year	Reinvestment Rate	Total Reinvested (EUR)	Operating CF	Capex	YoY Change
2021	1.67x	€15.30 Million	€9.19 Million	€1.80 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow